The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
June 30th 2025
Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
Exploring Emerging Targeted Therapies in Relapsed Small Cell Lung Cancer
1.0 Credit / Oncology, Lung Cancer
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non‒Small Cell Lung Cancer
0.5 Credit / Oncology, Lung Cancer
View More
Transforming Small Cell Lung Cancer Management With DLL3-Targeted Therapies
1.0 Credit / Oncology, Lung Cancer
View More
Cytokine Release Syndrome With Bispecific Antibodies: A Pharmacist's Guide to Safe Management
1.0 Credit / Hematologic Cancer, Lung Cancer, Oncology
View More
Advancements in Extensive-Stage Small Cell Lung Cancer Therapy: Integrating Clinical Evidence to Fill Gaps in ...
1.0 Credit / Oncology, Lung Cancer
View More
PBM Challenges and the Evolving Role of Oncology Pharmacists in Community Practices
0.75 Credit / Oncology, Law
View More
Aiming for Accuracy in Non-Small Cell Lung Cancer Treatment: Precision Strategies for Oncology Pharmacists
0.75 Credit / Oncology, Lung Cancer
View More
Perioperative Nivolumab Shows Long-Term EFS, Favorable OS in Resectable NSCLC
June 11th 2025Building on positive event-free survival (EFS) and overall survival (OS) rates in the original analysis of CheckMate 77T, new results indicate sustained survival over 3 years following treatment with nivolumab compared with placebo in non-small cell lung cancer (NSCLC).
Read More
Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression
June 6th 2025Granted accelerated approval by the FDA in 2024, tarlatamab continues to demonstrate efficacy and safety in patients with small cell lung cancer, with results showing improved overall survival and progression-free survival in patients who had progressed or previously received chemotherapy.
Read More
Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC
June 4th 2025Results from the NeoADAURA trial demonstrate the sustained efficacy of osimertinib in patients with epidermal growth factor receptor-mutated (EGFRm) non-small-cell lung cancer (NSCLC).
Read More
NCCN 2025: Immune Checkpoint Inhibitors Expand Treatment Options for Early-Stage NSCLC
March 29th 2025PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.
Read More
Optimizing Immunotherapy in Resectable NSCLC: Adjuvant, Neoadjuvant, and Perioperative Strategies
February 26th 2025The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.
Read More
Pharmacists Play a Vital Role in Addressing Patient Leakage in the Precision Medicine Care Continuum
February 6th 2025Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.
Watch
Bridging Gaps in Precision Medicine: Overcoming Patient Leakage and Advancing Personalized Care
February 5th 2025Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.
Watch